Consolidated Entities - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 216,802		$ 201,525
Receivables from collaborative arrangements	93,515		110,711
Prepaid expenses	5,576		1,367
Equity and long-term investments	544,437		483,845
Total assets	1,107,474		926,395
Liabilities and LLC Members' Equity
Current liabilities	109,227		5,807
Total liabilities and stockholders' equity	1,107,474		$ 926,395
Income statements
Total revenue	90,059	$ 85,518
Operating expenses	12,330	6,035
Income from operations	77,729	79,483
Income tax expense, net	6,860	19,736
Changes in fair values of equity and long-term investments	(9,411)	55,045
Net income	$ 37,858	109,695
Theravance Respiratory Company, LLC
CONSOLIDATED ENTITIES
Economic interest in LLC (in percent)	15.00%		15.00%
Assets
Cash and cash equivalents	$ 74,160		$ 50,713
Receivables from collaborative arrangements	29,309		42,492
Prepaid expenses	84		71
Equity and long-term investments	49,341		37,695
Total assets	152,894		130,971
Liabilities and LLC Members' Equity
Current liabilities	289		252
LLC members' equity	152,605		130,719
Total liabilities and stockholders' equity	152,894		$ 130,971
Income statements
Operating expenses	198	3,281
Income from operations	29,111	18,803
Income tax expense, net	1	0
Changes in fair values of equity and long-term investments	429	(483)
Net income	29,541	18,320
Theravance Respiratory Company, LLC | Royalty revenue from a related party
Income statements
Total revenue	$ 29,309	$ 22,084